Exagen's Shifting Narrative: New Analyst Price Target Sets New Expectations

The article discusses the change in price target for Exagen (XGN) and its implications for the company's risk-reward profile. The new target gives investors a fresh reference point for Exagen's fair value, based on one analyst's assumptions and modeling. The gap between the market price and the new target highlights the differing views of investors and analysts on Exagen. Future changes to the target may occur with new information, such as earnings or clinical milestones.